Compare Amgen, Inc. (AMGN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Viatris Inc — how do they compare? Amgen, Inc. trades at $417.92 (market cap $225.15B), while Viatris Inc trades at $16.06 (market cap $18.49B). The key difference: Amgen, Inc. is far larger — about 12.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.98%). Which is the better fit depends on your goals.
| AMGN | VTRS | |
|---|---|---|
Market Cap | $225.15B | $18.49B |
Sector | Health | Health |
52-Week High | $417.20 | $17.86 |
52-Week Low | $271.18 | $9.49 |
Enterprise Value | $268.47B | $30.61B |
Dividend Yield | 2.42% | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.84, up 0.85% today, near its R1 resistance of $418. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, and revenue exceeding $10 billion. Analyst consensus is bullish with 23 Buy ratings, a $392.53 price target, and technical indicators signaling a bullish trend from moving averages, though RSI levels suggest overbought conditions.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high debt levels and competitive pressures. The stock offers a dividend yield supported by consistent payouts, with investor sentiment bolstered by recent earnings outperformance and media coverage highlighting growth prospects.
Viatris (VTRS) trades at $16.04, down 1.47% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.69 exceeding expectations by 14.8%. Recent FDA approval for Gwyn Lo contraceptive patch and divestiture of Tyrvaya nasal spray demonstrate strategic portfolio optimization. Revenue trends show stabilization after declining from $16.3B in 2022 to $14.3B in 2025, with 2026 projections at $14.7B.
While Viatris shows operational strength with consistent cash flow generation and debt reduction, the company faces profitability challenges with negative net income margins and elevated P/E ratio of 236.2. Analyst sentiment is cautiously optimistic with 30.8% buy ratings, though the majority (61.5%) recommend hold. Key risks include ongoing margin pressure, generic drug pricing headwinds, and execution of strategic initiatives amid competitive pharmaceutical landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
